Links to articles in the current and previous 2 issues of this bulletin are displayed below.
To receive email notifications about new issues of this bulletin, please email: richard.fallis@healthcarelibrary.qub.ac.uk
Advances in the management of endometrial cancer
Assessment of a polygenic risk score in screening for prostate cancer
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia (new NICE guideline TA1049)
Fear of the cancer coming back: a metasynthesis of fear of recurrence in breast cancer
Intra-tumoral bacteria in breast cancer and intervention strategies
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (new NICE guideline TA1048)
Lymphatic transport in anti-tumor immunity and metastasis
Multimodal interventions for cachexia management (new Cochrane intervention review)
Next‐generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer (new Cochrane intervention review)
Pancreatic cancer (Lancet review)
Positron emission tomography‐adapted therapy for first‐line treatment in adults with Hodgkin lymphoma (new Cochrane intervention review)
Racial disparities in thyroid cancer outcomes: a systematic review
Testicular germ cell tumors: a review
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (new NICE guideline TA1046)
Advanced Drug Delivery Reviews (Feb); American Journal of Surgery (Feb); BMJ, The (Mar); Cochrane Library (Mar-Apr); JAMA (Mar); JAMA Otolaryngology - Head & Neck Surgery (Feb); Journal of Experimental Medicine (Feb); NEJM (Apr); NICE website (Mar); Obesity (Mar); Public Health (Jan); Public Health Nursing (Jan/Feb)
Advanced breast cancer: diagnosis and treatment (updated NICE guideline CG81)
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (new NICE guideline TA1034)
Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (updated NICE guideline HTE12)
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (new NICE guideline TA1030)
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (new NICE guideline TA1041)
Early and locally advanced breast cancer: diagnosis and management (updated NICE guideline NG101)
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (new NICE guideline TA1036)
Home hospitalization in palliative care for advanced cancer and dementia: a systematic review
Imaging in diagnosis and active surveillance for prostate cancer: a review
Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer (updated Cochrane intervention review)
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (new NICE guideline TA1040)
Ovarian cancer (updated NICE guideline QS18)
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (new NICE guideline TA1037)
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over (new NICE guideline TA1038)
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (new NICE guideline TA1039)
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (new NICE guideline TA1042)
Tebentafusp for treating advanced uveal melanoma (new NICE guideline IPG798)
Cochrane Library (Jan-Feb); JAMA Surgery (Jan); Journal of Pain and Symptom Management (Mar); Lancet, The (Jan); NICE website (Jan-Feb); Scientific Reports (Feb)
Cancer chemotherapy: incidence and predictors of 30-day mortality
Cancer pain self-management interventions in adults: scoping review
Cancer treatment refusal decisions in advanced cancer: a retrospective case–control study
CAR T cells and T-cell therapies for cancer: a translational science review
Colorectal cancer survivors’ quality of life: a qualitative study of unmet need
Decision tree algorithm to predict mortality in incurable cancer: a new prognostic model
Did Michelangelo paint a young adult woman with breast cancer in “The Flood” (Sistine Chapel, Rome)?
Digital health for cancer symptom management in palliative medicine: systematic review
Introducing palliative care in advanced cancer: a systematic review
Medical cannabis use in young adults with cancer: a self-reported survey study
Oesophageal cancer (Lancet seminar)
Opioid initiation timing and palliative care referrals in advanced cancer: retrospective study
The optimal timing of breast cancer surgery after COVID-19 infection: an observational study
Paediatric relapsed acute leukaemia: curative intent chemotherapy improves quality of life
Pain management effectiveness in advanced cancer: palliative care unit inpatient study
Preoperative chemoradiotherapy for resectable gastric cancer
RNA-loaded nanoparticles for the treatment of hematological cancers
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors
Advanced Drug Delivery Reviews (Nov); American Journal of Surgery, The (Nov); BMC Cancer (Nov); BMJ Supportive and Palliative Care (Nov-Dec); Breast, The (Dec); JAMA (Dec); Lancet, The (Nov); NEJM (Nov)
The Healthcare Library cannot guarantee the correctness or completeness of the information in these bulletins. The information is subject to change and we cannot guarantee it will remain up-to-date. It is your responsibility to check the accuracy and validity of the information. These bulletins are the property of the Healthcare Library; please credit us if re-using or distributing content from them.